Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain

LY2812223 [(1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid] was identified via structure-activity studies arising from the potent metabotropic glutamate mGlu2/3 receptor agonist LY354740 [(+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid] as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pharmacology and experimental therapeutics 2017-04, Vol.361 (1), p.190-197
Hauptverfasser: Felder, Christian C., Schober, Douglas A., Tu, Yuan, Quets, Anne, Xiao, Hongling, Watt, Marla, Siuda, Ed, Nisenbaum, Eric, Xiang, Chuanxi, Heinz, Beverly, Prieto, Lourdes, McKinzie, David L., Monn, James A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 197
container_issue 1
container_start_page 190
container_title The Journal of pharmacology and experimental therapeutics
container_volume 361
creator Felder, Christian C.
Schober, Douglas A.
Tu, Yuan
Quets, Anne
Xiao, Hongling
Watt, Marla
Siuda, Ed
Nisenbaum, Eric
Xiang, Chuanxi
Heinz, Beverly
Prieto, Lourdes
McKinzie, David L.
Monn, James A.
description LY2812223 [(1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid] was identified via structure-activity studies arising from the potent metabotropic glutamate mGlu2/3 receptor agonist LY354740 [(+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid] as an mGlu2-preferring agonist. This pharmacology was determined using stably transfected cells containing either the human mGlu2 or mGlu3 receptor. We extended the pharmacological evaluation of LY2812223 to native brain tissues derived from relevant species used for preclinical drug development as well as human postmortem brain tissue. This analysis was conducted to ensure pharmacological translation from animals to human subjects in subsequent clinical studies. A guanosine 5′-O-(3-[35S]thio)triphosphate (GTPγS) functional binding assay, a method for measuring Gi-coupled signaling that is inherent to the group 2 mGlu receptors, was used to evaluate LY2812223 pharmacology of native mGlu receptors in mouse, rat, nonhuman primate, and human cortical brain tissue samples. In native tissue membranes, LY2812223 unexpectedly acted as a partial agonist across all species tested. Activity of LY2812223 was lost in cortical membranes collected from mGlu2 knockout mice, but not those from mGlu3 knockout mice, providing additional support for mGlu2-preferring activity. Other signal transduction assays were used for comparison with the GTP binding assay (cAMP, calcium mobilization, and dynamic mass redistribution). In ectopic cell line–based assays, LY2812223 displayed near maximal agonist responses at the mGlu2 receptor across all assay formats, while it showed no functional agonist activity at the mGlu3 receptor except in the cAMP assay. In native brain slices or membranes that express both mGlu2 and mGlu3 receptors, LY2812223 displayed unexpected partial agonist activity, which may suggest a functional interplay between these receptor subtypes in the brain.
doi_str_mv 10.1124/jpet.116.237859
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1863219936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022356524195420</els_id><sourcerecordid>1863219936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-89b6fda8827a9e932ffe007a91011f9833896f63779479637c1f691c410bd6573</originalsourceid><addsrcrecordid>eNp1kL1uFDEUhS0EIkugpkMuaSbxz4zHLpcIEqRFRFFSUFlez_XG0Yw92B6kdHkH3jBPEocN6VLdU3z33HsOQh8pOaKUtcc3M5SqxBHjvezUK7SiHaMNoYS_RitCGGt4J7oD9C7nG0Jo2wr-Fh0wSbkkLV2hu8tkQh5N8TGYEZ9fmzQZG8e4u8XR4XIN-AcUs40lxdlbfDouxUymAGb4AizMJab7u7_nCRyk5MMOr3cx-Fzw5le9whjj2Id_Puvgp3rChAGfLZMJ-EsyPrxHb5wZM3x4mofo6tvXy5OzZvPz9PvJetNYLmVppNoKNxgpWW8UKM6cA0KqpoRSpyTnUgkneN-rtld1WuqEoralZDuIrueH6PPed07x9wK56MlnC-NoAsQlayoFZ1QpLip6vEdtijnXZHpO9fV0qynRj7Xrx9qrEnpfe9349GS-bCcYnvn_PVdA7QGoEf94SDpbD8HC4BPYoofoXzR_AFFNkYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1863219936</pqid></control><display><type>article</type><title>Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Felder, Christian C. ; Schober, Douglas A. ; Tu, Yuan ; Quets, Anne ; Xiao, Hongling ; Watt, Marla ; Siuda, Ed ; Nisenbaum, Eric ; Xiang, Chuanxi ; Heinz, Beverly ; Prieto, Lourdes ; McKinzie, David L. ; Monn, James A.</creator><creatorcontrib>Felder, Christian C. ; Schober, Douglas A. ; Tu, Yuan ; Quets, Anne ; Xiao, Hongling ; Watt, Marla ; Siuda, Ed ; Nisenbaum, Eric ; Xiang, Chuanxi ; Heinz, Beverly ; Prieto, Lourdes ; McKinzie, David L. ; Monn, James A.</creatorcontrib><description>LY2812223 [(1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid] was identified via structure-activity studies arising from the potent metabotropic glutamate mGlu2/3 receptor agonist LY354740 [(+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid] as an mGlu2-preferring agonist. This pharmacology was determined using stably transfected cells containing either the human mGlu2 or mGlu3 receptor. We extended the pharmacological evaluation of LY2812223 to native brain tissues derived from relevant species used for preclinical drug development as well as human postmortem brain tissue. This analysis was conducted to ensure pharmacological translation from animals to human subjects in subsequent clinical studies. A guanosine 5′-O-(3-[35S]thio)triphosphate (GTPγS) functional binding assay, a method for measuring Gi-coupled signaling that is inherent to the group 2 mGlu receptors, was used to evaluate LY2812223 pharmacology of native mGlu receptors in mouse, rat, nonhuman primate, and human cortical brain tissue samples. In native tissue membranes, LY2812223 unexpectedly acted as a partial agonist across all species tested. Activity of LY2812223 was lost in cortical membranes collected from mGlu2 knockout mice, but not those from mGlu3 knockout mice, providing additional support for mGlu2-preferring activity. Other signal transduction assays were used for comparison with the GTP binding assay (cAMP, calcium mobilization, and dynamic mass redistribution). In ectopic cell line–based assays, LY2812223 displayed near maximal agonist responses at the mGlu2 receptor across all assay formats, while it showed no functional agonist activity at the mGlu3 receptor except in the cAMP assay. In native brain slices or membranes that express both mGlu2 and mGlu3 receptors, LY2812223 displayed unexpected partial agonist activity, which may suggest a functional interplay between these receptor subtypes in the brain.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.116.237859</identifier><identifier>PMID: 28138041</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Brain - drug effects ; Brain - metabolism ; Bridged Bicyclo Compounds - metabolism ; Bridged Bicyclo Compounds - pharmacology ; Dose-Response Relationship, Drug ; Drug Partial Agonism ; Excitatory Amino Acid Agonists - metabolism ; Excitatory Amino Acid Agonists - pharmacology ; Humans ; Mice ; Mice, Knockout ; Protein Binding - drug effects ; Protein Binding - physiology ; Rats ; Rats, Sprague-Dawley ; Receptors, Metabotropic Glutamate - agonists ; Receptors, Metabotropic Glutamate - metabolism ; Translational Medical Research ; Triazoles - metabolism ; Triazoles - pharmacology</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2017-04, Vol.361 (1), p.190-197</ispartof><rights>2017 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-89b6fda8827a9e932ffe007a91011f9833896f63779479637c1f691c410bd6573</citedby><cites>FETCH-LOGICAL-c388t-89b6fda8827a9e932ffe007a91011f9833896f63779479637c1f691c410bd6573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28138041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Felder, Christian C.</creatorcontrib><creatorcontrib>Schober, Douglas A.</creatorcontrib><creatorcontrib>Tu, Yuan</creatorcontrib><creatorcontrib>Quets, Anne</creatorcontrib><creatorcontrib>Xiao, Hongling</creatorcontrib><creatorcontrib>Watt, Marla</creatorcontrib><creatorcontrib>Siuda, Ed</creatorcontrib><creatorcontrib>Nisenbaum, Eric</creatorcontrib><creatorcontrib>Xiang, Chuanxi</creatorcontrib><creatorcontrib>Heinz, Beverly</creatorcontrib><creatorcontrib>Prieto, Lourdes</creatorcontrib><creatorcontrib>McKinzie, David L.</creatorcontrib><creatorcontrib>Monn, James A.</creatorcontrib><title>Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>LY2812223 [(1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid] was identified via structure-activity studies arising from the potent metabotropic glutamate mGlu2/3 receptor agonist LY354740 [(+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid] as an mGlu2-preferring agonist. This pharmacology was determined using stably transfected cells containing either the human mGlu2 or mGlu3 receptor. We extended the pharmacological evaluation of LY2812223 to native brain tissues derived from relevant species used for preclinical drug development as well as human postmortem brain tissue. This analysis was conducted to ensure pharmacological translation from animals to human subjects in subsequent clinical studies. A guanosine 5′-O-(3-[35S]thio)triphosphate (GTPγS) functional binding assay, a method for measuring Gi-coupled signaling that is inherent to the group 2 mGlu receptors, was used to evaluate LY2812223 pharmacology of native mGlu receptors in mouse, rat, nonhuman primate, and human cortical brain tissue samples. In native tissue membranes, LY2812223 unexpectedly acted as a partial agonist across all species tested. Activity of LY2812223 was lost in cortical membranes collected from mGlu2 knockout mice, but not those from mGlu3 knockout mice, providing additional support for mGlu2-preferring activity. Other signal transduction assays were used for comparison with the GTP binding assay (cAMP, calcium mobilization, and dynamic mass redistribution). In ectopic cell line–based assays, LY2812223 displayed near maximal agonist responses at the mGlu2 receptor across all assay formats, while it showed no functional agonist activity at the mGlu3 receptor except in the cAMP assay. In native brain slices or membranes that express both mGlu2 and mGlu3 receptors, LY2812223 displayed unexpected partial agonist activity, which may suggest a functional interplay between these receptor subtypes in the brain.</description><subject>Animals</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Bridged Bicyclo Compounds - metabolism</subject><subject>Bridged Bicyclo Compounds - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Partial Agonism</subject><subject>Excitatory Amino Acid Agonists - metabolism</subject><subject>Excitatory Amino Acid Agonists - pharmacology</subject><subject>Humans</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Protein Binding - drug effects</subject><subject>Protein Binding - physiology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Metabotropic Glutamate - agonists</subject><subject>Receptors, Metabotropic Glutamate - metabolism</subject><subject>Translational Medical Research</subject><subject>Triazoles - metabolism</subject><subject>Triazoles - pharmacology</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kL1uFDEUhS0EIkugpkMuaSbxz4zHLpcIEqRFRFFSUFlez_XG0Yw92B6kdHkH3jBPEocN6VLdU3z33HsOQh8pOaKUtcc3M5SqxBHjvezUK7SiHaMNoYS_RitCGGt4J7oD9C7nG0Jo2wr-Fh0wSbkkLV2hu8tkQh5N8TGYEZ9fmzQZG8e4u8XR4XIN-AcUs40lxdlbfDouxUymAGb4AizMJab7u7_nCRyk5MMOr3cx-Fzw5le9whjj2Id_Puvgp3rChAGfLZMJ-EsyPrxHb5wZM3x4mofo6tvXy5OzZvPz9PvJetNYLmVppNoKNxgpWW8UKM6cA0KqpoRSpyTnUgkneN-rtld1WuqEoralZDuIrueH6PPed07x9wK56MlnC-NoAsQlayoFZ1QpLip6vEdtijnXZHpO9fV0qynRj7Xrx9qrEnpfe9349GS-bCcYnvn_PVdA7QGoEf94SDpbD8HC4BPYoofoXzR_AFFNkYw</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Felder, Christian C.</creator><creator>Schober, Douglas A.</creator><creator>Tu, Yuan</creator><creator>Quets, Anne</creator><creator>Xiao, Hongling</creator><creator>Watt, Marla</creator><creator>Siuda, Ed</creator><creator>Nisenbaum, Eric</creator><creator>Xiang, Chuanxi</creator><creator>Heinz, Beverly</creator><creator>Prieto, Lourdes</creator><creator>McKinzie, David L.</creator><creator>Monn, James A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201704</creationdate><title>Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain</title><author>Felder, Christian C. ; Schober, Douglas A. ; Tu, Yuan ; Quets, Anne ; Xiao, Hongling ; Watt, Marla ; Siuda, Ed ; Nisenbaum, Eric ; Xiang, Chuanxi ; Heinz, Beverly ; Prieto, Lourdes ; McKinzie, David L. ; Monn, James A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-89b6fda8827a9e932ffe007a91011f9833896f63779479637c1f691c410bd6573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Bridged Bicyclo Compounds - metabolism</topic><topic>Bridged Bicyclo Compounds - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Partial Agonism</topic><topic>Excitatory Amino Acid Agonists - metabolism</topic><topic>Excitatory Amino Acid Agonists - pharmacology</topic><topic>Humans</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Protein Binding - drug effects</topic><topic>Protein Binding - physiology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Metabotropic Glutamate - agonists</topic><topic>Receptors, Metabotropic Glutamate - metabolism</topic><topic>Translational Medical Research</topic><topic>Triazoles - metabolism</topic><topic>Triazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Felder, Christian C.</creatorcontrib><creatorcontrib>Schober, Douglas A.</creatorcontrib><creatorcontrib>Tu, Yuan</creatorcontrib><creatorcontrib>Quets, Anne</creatorcontrib><creatorcontrib>Xiao, Hongling</creatorcontrib><creatorcontrib>Watt, Marla</creatorcontrib><creatorcontrib>Siuda, Ed</creatorcontrib><creatorcontrib>Nisenbaum, Eric</creatorcontrib><creatorcontrib>Xiang, Chuanxi</creatorcontrib><creatorcontrib>Heinz, Beverly</creatorcontrib><creatorcontrib>Prieto, Lourdes</creatorcontrib><creatorcontrib>McKinzie, David L.</creatorcontrib><creatorcontrib>Monn, James A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Felder, Christian C.</au><au>Schober, Douglas A.</au><au>Tu, Yuan</au><au>Quets, Anne</au><au>Xiao, Hongling</au><au>Watt, Marla</au><au>Siuda, Ed</au><au>Nisenbaum, Eric</au><au>Xiang, Chuanxi</au><au>Heinz, Beverly</au><au>Prieto, Lourdes</au><au>McKinzie, David L.</au><au>Monn, James A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2017-04</date><risdate>2017</risdate><volume>361</volume><issue>1</issue><spage>190</spage><epage>197</epage><pages>190-197</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>LY2812223 [(1R,2S,4R,5R,6R)-2-amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic acid] was identified via structure-activity studies arising from the potent metabotropic glutamate mGlu2/3 receptor agonist LY354740 [(+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid] as an mGlu2-preferring agonist. This pharmacology was determined using stably transfected cells containing either the human mGlu2 or mGlu3 receptor. We extended the pharmacological evaluation of LY2812223 to native brain tissues derived from relevant species used for preclinical drug development as well as human postmortem brain tissue. This analysis was conducted to ensure pharmacological translation from animals to human subjects in subsequent clinical studies. A guanosine 5′-O-(3-[35S]thio)triphosphate (GTPγS) functional binding assay, a method for measuring Gi-coupled signaling that is inherent to the group 2 mGlu receptors, was used to evaluate LY2812223 pharmacology of native mGlu receptors in mouse, rat, nonhuman primate, and human cortical brain tissue samples. In native tissue membranes, LY2812223 unexpectedly acted as a partial agonist across all species tested. Activity of LY2812223 was lost in cortical membranes collected from mGlu2 knockout mice, but not those from mGlu3 knockout mice, providing additional support for mGlu2-preferring activity. Other signal transduction assays were used for comparison with the GTP binding assay (cAMP, calcium mobilization, and dynamic mass redistribution). In ectopic cell line–based assays, LY2812223 displayed near maximal agonist responses at the mGlu2 receptor across all assay formats, while it showed no functional agonist activity at the mGlu3 receptor except in the cAMP assay. In native brain slices or membranes that express both mGlu2 and mGlu3 receptors, LY2812223 displayed unexpected partial agonist activity, which may suggest a functional interplay between these receptor subtypes in the brain.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28138041</pmid><doi>10.1124/jpet.116.237859</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2017-04, Vol.361 (1), p.190-197
issn 0022-3565
1521-0103
language eng
recordid cdi_proquest_miscellaneous_1863219936
source MEDLINE; Alma/SFX Local Collection
subjects Animals
Brain - drug effects
Brain - metabolism
Bridged Bicyclo Compounds - metabolism
Bridged Bicyclo Compounds - pharmacology
Dose-Response Relationship, Drug
Drug Partial Agonism
Excitatory Amino Acid Agonists - metabolism
Excitatory Amino Acid Agonists - pharmacology
Humans
Mice
Mice, Knockout
Protein Binding - drug effects
Protein Binding - physiology
Rats
Rats, Sprague-Dawley
Receptors, Metabotropic Glutamate - agonists
Receptors, Metabotropic Glutamate - metabolism
Translational Medical Research
Triazoles - metabolism
Triazoles - pharmacology
title Translational Pharmacology of the Metabotropic Glutamate 2 Receptor–Preferring Agonist LY2812223 in the Animal and Human Brain
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Translational%20Pharmacology%20of%20the%20Metabotropic%20Glutamate%202%20Receptor%E2%80%93Preferring%20Agonist%20LY2812223%20in%20the%20Animal%20and%20Human%20Brain&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Felder,%20Christian%20C.&rft.date=2017-04&rft.volume=361&rft.issue=1&rft.spage=190&rft.epage=197&rft.pages=190-197&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.116.237859&rft_dat=%3Cproquest_cross%3E1863219936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1863219936&rft_id=info:pmid/28138041&rft_els_id=S0022356524195420&rfr_iscdi=true